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Background: Homoharringtonine (HHT) is a kind of cephalotaxus alkaloid used in traditional Chinese medicine.
Although HHT has been successfully used as a therapeutic agent for leukemia, the drug resistance and toxicity are
major concerns. MicroRNAs (miRNAs) have been identified to modulate cellular sensitivity to anticancer drugs. We
examined the synergistic action between miR-370 and HHT in vitro and in vivo.
Methods: The synergistic action between miR-370 and HHT was examined by flow cytometry. The effect of HHT on
miR-370 expression was determined by quantitative RT-PCR (qRT-PCR). The expression of miR-370 and Forkhead
box M1 (FoxM1) in 23 patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) and 10
patients with blast-crisis CML (CML-BP) as well as miR-370–targeted FoxM1 was determined by qRT-PCR and
western blot analysis.
Results: Ectopic expression of miR-370 sensitized the CML K562 cell line to HHT by targeting FoxM1, the major
regulator in cell proliferation and apoptosis. miR-370 significantly promoted HHT-mediated cell apoptosis and
miR-370 and HHT cooperated in affecting FoxM1 expression. As well, miR-370 was moderately upregulated after
HHT treatment in K562 cells. In addition, the expression of miR-370 was significantly reduced in CML patients as
compared with healthy controls. Furthermore, the expression of miR-370 was lower in CML-BP than CML-CP
patients.
Conclusions: MiR-370 sensitized K562 cells to HHT by inducing apoptosis in part by downregulation of FoxM1
expression. These findings may provide further information for CML treatment with HHT.
Keywords: miR-370, HHT, Cellular apoptosis, Chronic myeloid leukemiaBackground
Homoharringtonine (HHT), a plant alkaloid, is a trad-
itional Chinese medicine that has been successfully
used for leukemia treatment [1]. In the 1970s, a mix-
ture of HHT and harringtonine (HT) was first used
to treat acute myeloid leukemia (AML) and chronic
myeloid leukemia (CML) in China [2,3]. HHT inhibits
G1 and G2 protein synthesis, induces cell differenti-
ation and promotes cell apoptosis [4-6]. HHT was* Correspondence: chency@sdu.edu.cn
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reproduction in any medium, provided the oralso effective in the treatment of CML after inter-
feron α (IFN-α) failure [7].
HHT has synergistic activity with imatinib in imatinib-
resistant cell lines and primary cells from patients with
CML in blast crisis (CML-BP) [8]. Phase I and II studies
in the United States confirmed the clinical efficacy of
HHT in CML but documented a high incidence of car-
diovascular complications by intravenous administration
[9]. Studies in vitro also revealed a cooperative action
between HHT, Ara-C and IFN-α [10].
MicroRNAs (miRNAs) are small non-coding RNAs
that regulate gene expression by directly binding to
the 3′ untranslated regions (3′ UTR) of the target gene
mRNA, inducing translational inhibition or degradationtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12] and are involved in several biological processes such
as development, proliferation, differentiation, and apop-
tosis [13]. Recently, miRNAs were found active in the
chemosensitivity and chemoresistance of human cancer
cells [14,15]. For example, the inhibition of miR-21
sensitized K562 cells to arsenic trioxide [16]. miR-370 is
downregulated in gastric cancer [17], colorectal cancer
[18] and malignant human cholangiocytes [19]. Our
group also certified that miR-370 is downregulated in
AML and is involved in cell proliferation by directly
targeting the 3′ UTR of Forkhead box M1 (FoxM1), the
key positive transcriptional factor in the cell cycle and
found overexpressed in many tumor types [17,20]. How-
ever, the role of miR-370 in the chemosensitivity of
leukemic cells is unknown.
We aimed to define whether miR-370 has a synergistic
effect with HHT via FoxM1 in CML. We investigated a
lower dose of HHT to reduce its toxicity and maintain
its function.
Method
Patients and bone marrow samples
Patient bone marrow samples were collected between
June 2009 and December 2012 at the Department of
Hematology, Qilu Hospital, Shandong University School
of Medicine, Jinan, China. Bone marrow samples were
obtained from patients with newly diagnosed CML in
the chronic phase (CML-CP, n = 23) and blast crisis
(CML-BP, n = 10). Negative control samples came from
14 healthy volunteers. Mononuclear cells were isolated
from the samples by Ficoll-Hypaque density gradient
centrifugation, then stored at −80°C. The study was ap-
proved by the Ethics Committee of Shandong University
School of Medicine.
Cell culture and transfection
The human CML cell line K562 was cultured at 37°C, 95%
air and 5% CO2 in RPMI 1640 containing 10% heat-
inactivated fetal bovine serum (FBS) without antibiotics
(Gibco, Carlsbad, CA, USA). Cells were cultured on 6-well
plates for 18 to 24 h before experiments. K562 cells were
tranfected with miR-370 mimics (miR10000722-1-5) and
inhibitor (miR20000722-1; Ribobio, Guangzhou, China)
by use of Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA), then 6 h later transfected with HHT (0.015 μM).
K562 cells were tranfected with FoxM1 siRNA or FoxM1
overexpression plasmid with Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA, USA)for 72 h. FoxM1 siRNA was
designed and sythesized by Invitrogen. The sequence for
the FoxM1 siRNA was 5′-GACAACUGUCAAGUGUA
CCACUCUU-3′. FoxM1 overexpression plasmid was
constructed by our group and the primer sequences were
5′ the primer sequences were 5′-GAAGATCTTAACCATGAAAACTAGCCCCCG-3′(Forward) and 5′ -CGGAA
TTCGCTACTGTAGCTCAGGAATAAA-3′(Reverse).
RNA extraction and quantitative RT-PCR
The total RNA in human BM sample and K562 cells was
extracted by use of Trizol (Invitrogen, Carlsbad, CA,
USA). The expression of miR-370 was detected by quan-
titative RT-PCR (qRT-PCR) with the TaqMan miRNA
assay kit (Applied Biosystems, Foster City, CA, USA)
and U6 snRNA used as a control. In summary, total
RNAs were used for RT with specific primers, with the
reaction mixtures incubated at 16°C for 30 min, 42°C for
30 min and 85°C for 5 min. Then RT products were
used as templates for real time-PCR. PCR cycles were an
initial denaturation at 95°C for 10 min. Then the reac-
tion was repeated for 40 cycles of denaturing at 95°C for
10 s, annealing and synthesis at 60°C for 60 s. qRT-PCR
involved use of the ABI7500 sequence detector (Applied
Biosystems, Foster City, CA, USA). The level of miR-370
expression was normalized by U6 snRNA. The mRNA
level of FoxM1 was determined by RT and SYBR-Green
real-time PCR assay. cDNA was synthesized with a ran-
dom primer and MMLV reverse transcriptase (Fermentas,
Canada). Real-time PCR involved the ABI7500 sequence
detector (Applied Biosystems, Foster City, CA, USA). The
PCR primer sequences were for FoxM1, 5′-TGCAGC
TAGGATGTGAATCTTC-3′ (Forward) and 5′-GGAGCC
CAGTCCATCAGAACT-3′ (Reverse); β-actin: 5′-AGTTG
CGTTACACCCTTTCTTG-3′ (Forward) and 5′-CACC
TTCACCGTTCCAGTTTT-3′ (Reverse). FoxM1 mRNAs
were normalized to β-actin expression. Expression was
calculated as the change relative to the control (2-ΔΔCt).
Western blot analysis
The cells were lyzed in protein lysis buffer in the pres-
ence of proteinase inhibitor (Biocolor BioScience &
Technology, Shanghai). Proteins were separated by SDS-
PAGE and transferred to PVDF membranes, which were
probed with primary antibodies against FoxM1 (1:500,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
β-actin (1:20000, Sigma) for 2 h under room temperature
followed by horseradish peroxidase-labeled goat-anti-
rabbit IgG (1:6000, Santa Cruz Biotechnology) for
2 h. The signals were detected by enhanced chemilu-
minescence. β-actin acted as a loading control.
Flow cytometry
K562 cells were seeded in 6-well plates for treatment with
miR-370 and/or HHT (0.015 μM) for various times. Then
106 cells were harvested for each group and washed twice
with PBS. The cells were double-stained with FITC-
conjugated Annexin V and propidium iodide (PI). Apop-
tosis and necrosis were analyzed by quadrant statistics.
Data are shown as the percentage of apoptotic cells.
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All the experiments were carried out in triplicate. Data
are expressed as mean ± SEM. Differences were calcu-
lated by two-tailed Student’s t test or one-way ANOVA
for experiments with more than 2 subgroups by use of
SPSS 13.0 (SPSS Inc., Chicago, IL). Statistical signifi-
cance was defined as P < 0.05.Results
Upregulation of miR-370 sensitized K562 cells to HHT
MiR-370 mimics was transfected into K562 cells alone
or with 0.015 μM HHT after 6 h. According to MTT
assay of K562 cell proliferation, IC50 values of HHT was
determined and 0.015 μM HHT was selected (Additional
file 1: Figure S1). After 72 h incubation, the proportion
of apoptotic K562 cells was detected by flow cytometry
by double-staining with PI and Annexin V. Both miR-
370 mimics and HHT induced cell apoptosis (Figure 1)
(P < 0.05, Additional file 2: Figure S2). More importantly,
miR-370 promoted HHT-induced cell apoptosis (P < 0.05,
Additional file 2: Figure S2).Figure 1 MiR-370 enhanced HHT-induced cell apoptosis in K562 cells
incubation with 0.015 μM HHT or both. NC represents random oligonucleo
K562 cells by double-staining with propidium iodide (PI) and Annexin V. Th
and Q4 cells. Q2 is late apoptosis and Q4 early apoptosis. Results are fromThe mRNA level of miR-370 in K562 cells was signifi-
cantly increased with the transfection of miR-370 mimics
as compared with the control (P < 0.01) (Figure 2A).
The expression of miR-370 was greater with HTT +
miR-370 mimics as compared with miR-370 mimics
alone (P < 0.01), which suggested that the upregulation
of miR-370 sensitized K562 cells to HHT for apoptosis
and the possible effect of HTT on miR-370 expression.
Increased sensitivity to HHT with upregulation of miR-370
was partially attributed to FoxM1 downregulation
To further determine the correlation between HHT,
miR-370 and FoxM1 in the CML K562 cell line, we
checked the expression of FoxM1 in cells. After transfec-
tion with miR-370 mimics or inhibitor, the expression of
miR-370 was overexpressed and downregulated, respect-
ively (Figure 2A). As well, the mRNA and protein levels
of FoxM1 were inhibited with miR-370 mimics and
increased with miR-370 inhibitor, so the expression of
miR-370 was negatively related to that of FoxM1 in
K562 cells (Figure 2A and 2B). Meanwhile, the expres-
sion of FoxM1 was further inhibited with HHT +miR-. Cells were harvested 72 h after transfection of miR-370 mimics and
tides for the negative control of miR-370 mimics. Flow cytometry of
e proportions of apoptotic cells are in the upper right corners of Q2
3 independent experiments.
Figure 2 MiR-370 enhanced HHT-induced apoptosis dependent in part on FoxM1 in K562 cells. (A) The mRNA expression of FoxM1 was
regulated by miR-370 mimics or inhibitor at the transcriptional level. Quantitative RT-PCR (qRT-PCR) analysis of miR-370 and FoxM1 and the
loading control U6 snRNA. The time for transfection of miR-370 and incubation of 0.015 μM HHT is 72 h. Data are mean ± SEM of 3 independent
experiments. (B) Western blot analysis of FoxM1 protein level after treatment with miR-370 mimics and inhibitor. β-actin was a loading control.
(C) after transfection with miR-370 mimics with or without HHT. (D) Quantitative flow cytometry of the apoptosis of K562 cells. Cells were
harvested 72 h after transfection of miR-370 mimics or FoxM1 overexpression plasmid. The results are from 3 independent experiments. (E) Cells
were harvested 72 h after transfection of miR-370 inhibitor or FoxM1 special siRNA (5 μM). Quantitative flow cytometry of the apoptosis of K562
cells. The results are from 3 independent experiments. *P < 0.05, **P < 0.01.
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(P < 0.05, Figure 2A). The protein expression of FoxM1
was inhibited with HHT +miR-370 mimics as compared
with HHT +NC and miR-370 mimics alone (Figure 2C).
Thus, FoxM1 had a role in increased sensitivity to HHT
with upregulation of miR-370.
To further identify the role of FoxM1, we checked its
function in cell apoptosis induced by miR-370. After
transfection with miR-370 mimics or FoxM1 siRNA,
both miR-370 mimics and FoxM1 siRNA induced cell
apoptosis (P < 0.05, Figure 2D, 2E). Otherwise, miR-370
inhibitor and FoxM1 overexpression plasmid inhibited
cell apoptosis (P < 0.01, Figure 2E; P < 0.05, Figure 2D).
When FoxM1 overexpression plasmid was transfected
into K562 cells with miR-370 mimics to reverse the
expression of FoxM1, the apoptosis was partially re-
versed. However, the FoxM1 siRNA that inhibited the
miR-370-inhibitor–induced overexpression of FoxM1neutralized the inhibited apoptosis induced by anti-miR-
370 treatment.HHT mediated the upregulation of miR-370 in K562 cells
To further investigate the effect of HHT on miR-370
expression, we detected the expression of miR-370 and
its target FoxM1 with incubation of HHT in K562 cells.
In cells incubated with HHT at different concentrations
(0.015 and 0.03 μM) for 72 h, the level of mature miR-
370 increased to about 37-fold and 77-fold that of the
control (P < 0.01; Figure 3A). FoxM1 mRNA and pro-
tein expression was dose-dependently downregulated
(P < 0.01; Figure 3A, 3C). Furthermore, after K562 cells
were incubated with HHT for 72 and 96 h, the level of
miR-370 was upregulated (P < 0.05; P < 0.01), which was
accompanied by the inhibition of FoxM1 mRNA and
protein expression (P < 0.05; P < 0.01, Figure 3B, 3D).
Figure 3 HHT regulated mature miR-370 level in K562 cells. K562 cells were incubated with HHT or PBS and harvested after 72 or 96 h.
Real-time PCR analysis of the mRNA expression of mature miR-370 and FoxM1. Western blot analysis of FoxM1 protein level. (A) HHT increased
the expression of mature miR-370 in a dose-dependent manner. The mRNA level of FoxM1 decreased in K562 cells with HHT incubation,
**P < 0.01 vs control, Data are mean ± SEM of 3 independent experiments. (B) HHT regulated the expression of miR-370 and FoxM1 time-dependently.
*P < 0.05, **P < 0.01 vs control, Data are mean ± SEM of 3 independent experiments. (C-D) Western blot analyis of protein level of FoxM1 after HHT
treatment at different concentrations or different times. β-actin was a loading control. (E) The protein expression of FoxM1 with incubation of HHT and
miR-370 inhibitor. The results were confirmed by 3 independent experiments. (F) Anti-miR-370 treatment partially reversed HHT-induced apoptosis.
Cells were treated with 0.015 μM HHT + NC or 0.015 μM HHT +miR-370 inhibitor for 72 h. Flow cytometry of K562 cells by double-staining with PI and
Annexin V. The proportion of apoptotic cells is shown in the upper right corners of Q2 and Q4 cells. The results are from 3 independent experiments.
(G) Mature miR-370 expression was downregulated in K562 cells treated with HHT +miR-370 inhibitor, **P < 0.01 vs HHT + NC group. FoxM1 mRNA
level was upregulated, *P < 0.05 vs HHT +NC group. Data are mean ± SEM of 3 independent experiments.
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in K562 cells.
To further detect the importance of miR-370 in HHT-
induced apoptosis, miR-370 inhibitor was transfected into
K562 cells with 0.015 μM HHT for 72 h. The miR-370
inhibitor partially reversed HHT-induced cell apoptosis as
compared with the control (Figure 3F) (P < 0.05, Additional
file 3: Figure S3). MiR-370 expression was inhibited and
FoxM1 expression was upregulated (Figure 3E, 3G). There-
fore, the HHT–miR-370–FoxM1 axis might be a new regu-
latory mechanism in HHT-induced apoptosis.Misregulation of miR-370 and FoxM1 in bone marrow
from CML-CP and CML-BP patients
MiR-370 expression was analyzed in bone marrow sam-
ples from 23 patients with newly diagnosed CML-CP
and 10 with CML-BP. The clinical characteristics of
CML patients are in Additional file 4: Table S1. The level
of miR-370 was lower in CML patients than healthy
controls. Furthermore, miR-370 expression was lower in
CML-BP than CML-CP patients (Figure 4A).
The mRNA level of FoxM1 was higher in patients with
CML-BP than CML-CP, with the expression lowest in
Figure 4 The expression of miR-370 and FoxM1 in CML-CP and CML-BP patients. (A) Real-time PCR analysis of the relative expression of
mature miR-370 in 23 CML-CP patients, 10 CML-BP patients and 14 healthy controls. *P < 0.05 vs control and **P < 0.01 vs CML-CP. Data are mean ±
SEM. (B, C) qRT-PCR and western blot analysis of FoxM1 mRNA and protein levels. **P < 0.01 vs control and **P < 0.01 vs CML-CP. Data are mean ±
SEM. The results were confirmed by 3 independent experiments.
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association with miR-370 expression. The FoxM1 pro-
tein expression findings were consistent with the mRNA
findings, for lowest level in healthy controls, higher in
CML-CP patients and highest in CML-BP patients
(Figure 4C).
Discussion
HHT is a traditional Chinese medicine that has been
successfully used for treatment of leukemia [1]. We
found that miR-370, which directly targets FoxM1, could
sensitize K562 cells to HHT by inducing cell apoptosis,
which may give hope for miRNA-based CML therapy
with less drug toxicity.
MiRNAs are endogenous substances that translation-
ally inhibit or degrade target gene mRNA by binding to
the 3′ UTR of target gene mRNA. Many studies have
shown that miR-370 is commonly deregulated in mul-
tiple human tumors and implicated in various aspects of
tumors, including growth, metastasis and senescence
[18-22]. Our group found that miR-370 is involved in
AML and Helicobacter pylori-induced gastric carcino-
genesis by directly targeting FoxM1 [17,20]. In this re-
search, we found that ectopic expression of miR-370
induced apoptosis in the CML cell line K562. More im-
portant, miR-370 mimics could improve HHT-induced
apoptosis. HHT plays an important role in antitumor
therapy by inducing apoptosis [23]. Recent research also
showed that HHT was effective when combined with
other agents for its cardiotoxicity at relative high con-
centration [24]. The combination of HHT and miR-370shows a new way to induce apoptosis in CML K562 cells
with less concentration of HHT and therefore fewer side
effects. Considering the characteristic of miRNAs in
human bodies, this combination of HHT and miR-370
might have clinical value.
To assess the role of abnormally expressed miRNA in
human cancer and develop miRNA-based gene therapy,
target genes of miRNAs must be identified. Increasing
evidence has shown that miR-370 regulates a number
of target genes, including Wilms tumor gene on the X
chromosome [25], insulin receptor substrate 1 [22],
Forkhead box protein O1 [26] and FoxM1 in AML by
our group [20]. FoxM1 is the master positive regulator
of the cell cycle and is related to cell proliferation, cell
cycle progression and apoptosis [27-34]. Furthermore,
recent studies suggest that FoxM1 mediates chemore-
sistance. For example, overexpression of FoxM1 partially
protected cancer cells against thiazole antibiotic-mediated
cell death [34] and enhanced hepatoma cell resistance to
TNF-α–induced apoptosis [30]. FoxM1 knockdown sensi-
tized cancer cells to apoptotic cell death induced by pro-
teasome inhibitors such as MG-132, bortezomib and
thiostrepton [35]. Inhibition of FoxM1, combined with
oxaliplatin treatment, significantly promoted the senes-
cence of hepatocellular carcinoma cells [36]. Here, we
confirmed that FoxM1, as a target gene of miR-370, par-
tially mediated the chemosensitivity of K562 cells to HHT.
FoxM1 overexpression reversed cell apoptosis induced by
miR-370 mimics in part, and FoxM1 siRNA neutralized
the inhibition of apoptosis induced by miR-370 inhibitor.
The increased sensitivity of K562 cells to HHT-induced
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370, was at least in part related to FoxM1.
We also found that HHT +miR-370 mimics upregulated
the expression of miR-370 to a higher level as compared
with miR-370 mimics alone. We further checked the
mechanism among HHT, miR-370 and FoxM1. HHT
upregulated the level of mature miR-370 time- and dose-
dependently, and anti-miR-370 treatment reversed HHT-
induced apoptosis, so the miR-370–FoxM1 pathway might
be a new mechanism for HHT-induced apoptosis with a
positive feedback loop between miR-370 and HHT. The
regulatory mechanism in the HHT–miR-370–FoxM1 axis
needs further investigatation.
We identified the role of miR-370 and FoxM1 in human
CML specimens. The expression of miR-370 was lower in
CML-CP and least in CML-BP patients as compared with
healthy controls. In contrast, the mRNA and protein levels
of FoxM1 were higher in CML-CP and highest in CML-
BP patients as compared with controls. These results sug-
gest the important function of miR-370 and FoxM1 in
CML and their negative association. Recent research has
showed miR-370 could be upregulated by 5-Aza-CdR, a
DNA methylation inhibitor already in clinical practice
[20,22]. So the combination of HHT and 5-Aza-CdR
might give new insight into the treatment of leukemia.
Further studies will need to confirm this hypothesis.
Conclusions
In summary, ectopic expression of miR-370 sensitized
K562 cells to HHT and partially targeted FoxM1 by indu-
cing apoptosis. Meanwhile, HHT upregulated the level of
mature miR-370. These findings might point to a way to
reduce the high tolerance and toxicity of HHT and could
be good news to the patients resistant to tyrosine kinase
inhibitors. Therefore, a strategy combining miR-370 and
HHT might be an effective clinical treatment for CML.
Additional files
Additional file 1: Figure S1. MTT assay of K562 cell proliferation. IC50
values of HHT determined by chi-square test with P> 0. 05, suggesting
that curve fitting is good.
Additional file 2: Figure S2. Flow cytometry of apoptosis of K562 cells
with miR-370 mimics and HHT+miR-370 mimics, *P<0.05.
Additional file 3: Figure S3. Flow cytometry of apoptosis of K562 cells
with HHT+miR-370 inhibitor and HHT+NC. *P<0.05 vs control.
Additional file 4: Table S1. Patient characteristics.
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